NASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price & News $188.26 +2.26 (+1.22%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$184.06▼$188.8750-Day Range$185.92▼$212.0552-Week Range$120.43▼$242.97Volume426,725 shsAverage Volume599,164 shsMarket Capitalization$23.44 billionP/E RatioN/ADividend YieldN/APrice Target$247.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Alnylam Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside31.3% Upside$247.20 Price TargetShort InterestBearish4.11% of Shares Sold ShortDividend StrengthN/ASustainability-1.52Upright™ Environmental ScoreNews Sentiment0.74Based on 11 Articles This WeekInsider TradingSelling Shares$7.13 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.46) to ($3.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector175th out of 1,012 stocksPharmaceutical Preparations Industry69th out of 495 stocks 4.4 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 15 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $247.20, Alnylam Pharmaceuticals has a forecasted upside of 31.3% from its current price of $188.26.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.11% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently increased by 0.79%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alnylam Pharmaceuticals is -1.52. Previous Next 3.2 News and Social Media Coverage News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Alnylam Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest17 people have searched for ALNY on MarketBeat in the last 30 days. This is an increase of 750% compared to the previous 30 days.MarketBeat Follows5 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,131,842.00 in company stock.Percentage Held by InsidersOnly 1.40% of the stock of Alnylam Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($6.46) to ($3.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -21.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -21.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Alnylam Pharmaceuticals (NASDAQ:ALNY) StockAlnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.Read More Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Stock News HeadlinesMay 27, 2023 | americanbankingnews.comHead to Head Contrast: Alnylam Pharmaceuticals (NASDAQ:ALNY) & Syros Pharmaceuticals (NASDAQ:SYRS)May 26, 2023 | msn.comU.S. FDA approves Lexicon Pharma's drug for heart failureMay 28, 2023 | Behind the Markets (Ad)NOTICE: Your retirement is in immediate dangerSoon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>May 26, 2023 | msn.comPfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccinesMay 23, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)May 22, 2023 | markets.businessinsider.comAnalyst Says Alnylam's New Patisiran Data Shows Disease Slowing With Early Intervention, But Survival Benefit Remains Of InterestMay 22, 2023 | finance.yahoo.comAlnylam (ALNY) Reports Positive Results From APOLLO-B StudyMay 19, 2023 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Analysts at StockNews.comMay 28, 2023 | Stansberry Research (Ad)Bank Collapse Causes Gold Prices to SoarSilicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.May 19, 2023 | americanbankingnews.comAnalysts Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $247.20May 18, 2023 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.3%May 16, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Disc Medicine (IRON)May 15, 2023 | marketwatch.comFamilial Amyloid Polyneuropathy Therapeutic Market Insights [2023]| Explained Current Growth for Upcoming Period 2031May 13, 2023 | marketwatch.comSystemic Amyloidosis Market Forecast and Analysis: 2023-2031May 8, 2023 | markets.businessinsider.comCitigroup Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)May 8, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Alnylam Pharma (ALNY)May 8, 2023 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Lifted to Buy at StockNews.comMay 6, 2023 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Outperform at BMO Capital MarketsMay 6, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Qiagen (QGEN) and Teleflex (TFX)May 5, 2023 | finance.yahoo.comAlnylam (ALNY) Q1 Earnings Beat, Product Sales Drive RevenuesMay 5, 2023 | markets.businessinsider.comAlnylam Pharma (ALNY) Receives a Buy from BMO CapitalMay 5, 2023 | markets.businessinsider.comNeedham Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)May 5, 2023 | msn.comNeedham Reiterates Alnylam Pharmaceuticals (ALNY) Buy RecommendationMay 5, 2023 | msn.comBMO Capital Upgrades Alnylam Pharmaceuticals (ALNY)May 4, 2023 | markets.businessinsider.comBerenberg Bank Keeps Their Hold Rating on Alnylam Pharma (ALNY)May 4, 2023 | msn.comAlnylam Clocks ~50% Revenue Growth In Q1 On Solid Commercial ExecutionMay 4, 2023 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Company Calendar Last Earnings5/04/2023Today5/28/2023Next Earnings (Estimated)7/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,002Year Founded2002Price Target and Rating Average Stock Price Forecast$247.20 High Stock Price Forecast$415.00 Low Stock Price Forecast$143.00 Forecasted Upside/Downside+31.3%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)($8.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,131,160,000.00 Net Margins-93.13% Pretax Margin-92.70% Return on Equity-1,287.80% Return on Assets-30.86% Debt Debt-to-Equity RatioN/A Current Ratio3.77 Quick Ratio3.58 Sales & Book Value Annual Sales$1.04 billion Price / Sales22.60 Cash FlowN/A Price / Cash FlowN/A Book Value($2.08) per share Price / Book-90.51Miscellaneous Outstanding Shares124,530,000Free Float122,783,000Market Cap$23.44 billion OptionableOptionable Beta0.48 Social Links Key ExecutivesYvonne L. GreenstreetChief Executive Officer & DirectorAkshay K. VaishnawPresidentJeffrey V. PoultonChief Financial Officer & Executive Vice PresidentPushkal P. GargChief Medical Officer & EVP-Medical AffairsJames P. BilottaChief Information Officer & SVPKey CompetitorsBioMarin PharmaceuticalNASDAQ:BMRNUnited TherapeuticsNASDAQ:UTHRIonis PharmaceuticalsNASDAQ:IONSRegeneron PharmaceuticalsNASDAQ:REGNVertex PharmaceuticalsNASDAQ:VRTXView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 3,227 shares on 5/26/2023Ownership: 0.007%Toroso Investments LLCSold 473 shares on 5/23/2023Ownership: 0.003%Ameriprise Financial Inc.Bought 155,795 shares on 5/22/2023Ownership: 0.163%New York State Common Retirement FundSold 6,610 shares on 5/18/2023Ownership: 0.119%International Biotechnology Trust PLCBought 8,600 shares on 5/18/2023Ownership: 0.037%View All Insider TransactionsView All Institutional Transactions ALNY Stock - Frequently Asked Questions Should I buy or sell Alnylam Pharmaceuticals stock right now? 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 6 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALNY shares. View ALNY analyst ratings or view top-rated stocks. What is Alnylam Pharmaceuticals' stock price forecast for 2023? 21 brokerages have issued twelve-month target prices for Alnylam Pharmaceuticals' stock. Their ALNY share price forecasts range from $143.00 to $415.00. On average, they predict the company's stock price to reach $247.20 in the next year. This suggests a possible upside of 31.3% from the stock's current price. View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts. How have ALNY shares performed in 2023? Alnylam Pharmaceuticals' stock was trading at $237.65 on January 1st, 2023. Since then, ALNY shares have decreased by 20.8% and is now trading at $188.26. View the best growth stocks for 2023 here. When is Alnylam Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023. View our ALNY earnings forecast. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating analysts' consensus estimates of ($1.97) by $0.57. The biopharmaceutical company had revenue of $319.29 million for the quarter, compared to analyst estimates of $312.53 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 1,287.80% and a negative net margin of 93.13%. Alnylam Pharmaceuticals's revenue was up 49.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.00) earnings per share. What ETFs hold Alnylam Pharmaceuticals' stock? ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX), VanEck Biotech ETF (BBH), American CenturyFocused Dynamic Growth ETF (FDG), First Trust NYSE Arca Biotechnology Index Fund (FBT) and Principal Healthcare Innovators ETF (BTEC). What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings? Alnylam Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.46 billion, compared to the consensus revenue estimate of $1.39 billion. What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO? 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD). What is Alnylam Pharmaceuticals' stock symbol? Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY." Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (10.58%), Baillie Gifford & Co. (6.97%), BlackRock Inc. (6.87%), Wellington Management Group LLP (4.94%), Price T Rowe Associates Inc. MD (3.19%) and Dodge & Cox (3.13%). Insiders that own company stock include Akshay Vaishnaw, Barry E Greene, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alnylam Pharmaceuticals' stock price today? One share of ALNY stock can currently be purchased for approximately $188.26. How much money does Alnylam Pharmaceuticals make? Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $23.44 billion and generates $1.04 billion in revenue each year. The biopharmaceutical company earns $-1,131,160,000.00 in net income (profit) each year or ($8.69) on an earnings per share basis. How many employees does Alnylam Pharmaceuticals have? The company employs 2,002 workers across the globe. How can I contact Alnylam Pharmaceuticals? Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101. This page (NASDAQ:ALNY) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.